Arrow Capital Pty Ltd Has $6.37 Million Holdings in Pfizer Inc. $PFE

Arrow Capital Pty Ltd raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 30.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 250,000 shares of the biopharmaceutical company’s stock after buying an additional 57,671 shares during the quarter. Pfizer comprises 0.1% of Arrow Capital Pty Ltd’s portfolio, making the stock its 3rd largest holding. Arrow Capital Pty Ltd’s holdings in Pfizer were worth $6,370,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after acquiring an additional 10,198,330 shares during the period. Norges Bank bought a new stake in Pfizer during the 2nd quarter worth approximately $2,270,157,000. Fisher Asset Management LLC increased its holdings in Pfizer by 1.9% during the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after acquiring an additional 897,786 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 2.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after purchasing an additional 1,135,457 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Pfizer by 8.6% in the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after purchasing an additional 3,296,415 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

PFE stock opened at $26.60 on Friday. The firm has a 50 day simple moving average of $26.50 and a two-hundred day simple moving average of $25.52. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock has a market cap of $151.23 billion, a PE ratio of 19.56 and a beta of 0.47. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter last year, the company posted $0.63 EPS. The business’s quarterly revenue was down 1.2% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. TD Cowen reissued a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. UBS Group began coverage on Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. Finally, Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $28.05.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.